Literature DB >> 26167810

Resveratrol Ameliorates Pressure Overload-induced Cardiac Dysfunction and Attenuates Autophagy in Rats.

Lingjun Wang1, Mengxi Gao, Jie Chen, Zhongqi Yang, Jinghe Sun, Zhaohui Wang, Xiwen Huang, Tianhui Yuan, Xiaoxiao Shen, Shaoxiang Xian.   

Abstract

Pressure overload has an important role in heart failure, inducing excessive autophagy in cardiac myocytes that is considered to be pathogenic. Resveratrol has been reported to improve cardiac dysfunction induced by pressure overload, but it has been unclear whether resveratrol ameliorates cardiac dysfunction by regulating autophagy. In this study, heart failure was induced in rats by constriction of the abdominal aorta. Four weeks after surgery, the rats with heart failure were randomized to treatment with resveratrol (8 mg · kg(-1) · d(-1) by intraperitoneal injection) for 28 days or to intraperitoneal injection of the vehicle (propylene glycol) alone. Echocardiography was performed to assess cardiac function. Expression of brain natriuretic peptide messenger RNA in the left ventricle was detected by real-time polymerase chain reaction, whereas expression of proteins associated with autophagy (beclin-1 and lamp-1) was detected by western blotting and immunohistochemistry. Furthermore, autophagic vacuoles were detected in the heart by transmission electron microscopy, and the myocardial ATP content was measured by the bioluminescence method. Treatment with resveratrol significantly improved cardiac dysfunction and reduced brain natriuretic peptide expression in rats with heart failure. Resveratrol down-regulated beclin-1 and lamp-1 expression and also inhibited the formation of autophagic vacuoles in failing hearts. Furthermore, resveratrol restored the myocardial ATP level and reduced phosphorylation of AMP-activated protein kinase at Thr172. These results suggest that resveratrol may inhibit autophagy through inactivation of AMP-activated protein kinase and restoration of ATP in heart failure induced by pressure overload. Accordingly, resveratrol may be beneficial for patients with hypertensive heart disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26167810     DOI: 10.1097/FJC.0000000000000290

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

Review 1.  Autophagy: A Lysosome-Dependent Process with Implications in Cellular Redox Homeostasis and Human Disease.

Authors:  Stefan W Ryter; Divya Bhatia; Mary E Choi
Journal:  Antioxid Redox Signal       Date:  2018-03-28       Impact factor: 8.401

2.  Trimetazidine attenuates pressure overload-induced early cardiac energy dysfunction via regulation of neuropeptide Y system in a rat model of abdominal aortic constriction.

Authors:  Ailan Chen; Wanglin Li; Xinyu Chen; Yuechun Shen; Wenjun Dai; Qi Dong; Xinchun Li; Caiwen Ou; Minsheng Chen
Journal:  BMC Cardiovasc Disord       Date:  2016-11-17       Impact factor: 2.298

3.  Resveratrol alleviates hypoxia/reoxygenation injury‑induced mitochondrial oxidative stress in cardiomyocytes.

Authors:  Tao Li; Linlin Chen; Yiyan Yu; Binbin Yang; Pengyun Li; Xiao-Qiu Tan
Journal:  Mol Med Rep       Date:  2019-02-07       Impact factor: 2.952

Review 4.  AMPK: a therapeutic target of heart failure-not only metabolism regulation.

Authors:  Xuan Li; Jia Liu; Qingguo Lu; Di Ren; Xiaodong Sun; Thomas Rousselle; Yi Tan; Ji Li
Journal:  Biosci Rep       Date:  2019-01-03       Impact factor: 3.840

5.  Resveratrol Supplementation Protects Against Nicotine-Induced Kidney Injury.

Authors:  Anand Ramalingam; Thulasiprevinnah Santhanathas; Shafreena Shaukat Ali; Satirah Zainalabidin
Journal:  Int J Environ Res Public Health       Date:  2019-11-12       Impact factor: 3.390

6.  Targeting mitochondrial reactive oxygen species-mediated oxidative stress attenuates nicotine-induced cardiac remodeling and dysfunction.

Authors:  Anand Ramalingam; Siti Balkis Budin; Norsyahida Mohd Fauzi; Rebecca H Ritchie; Satirah Zainalabidin
Journal:  Sci Rep       Date:  2021-07-05       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.